Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers

Am J Surg Pathol. 2015 Nov;39(11):1548-57. doi: 10.1097/PAS.0000000000000476.

Abstract

Epithelial ovarian cancer (EOC) consists of 5 major histotypes: high-grade serous carcinoma (HGSC), endometrioid carcinoma (EC), clear cell carcinoma (CCC), mucinous carcinoma (MC), and low-grade serous carcinoma (LGSC). Each can have a broad spectrum of morphologic appearances, and 1 histotype can closely mimic histopathologic features more typical of another. Historically, there has been a relatively high frequency of mixed, defined by 2 or more distinct histotypes present on the basis of routine histopathologic assessment, histotype carcinoma diagnoses (3% to 11%); however, recent immunohistochemical (IHC) studies identifying histotype-specific markers and allowing more refined histotype diagnoses suggest a much lower incidence. We reviewed hematoxylin and eosin-stained slides from 871 cases of EOC and found the frequency of mixed carcinomas to be 1.7% when modern diagnostic criteria are applied. Through international collaboration, we established a cohort totaling 22 mixed EOCs, consisting of 9 EC/CCC, 4 EC/LGSC, 3 HGSC/CCC, 2 CCC/MC, and 4 other combinations. We interrogated the molecular differences between the different components of each case using IHC, gene expression, and hotspot sequencing analyses. IHC data alone suggested that 9 of the 22 cases were not mixed tumors, as they presented a uniform immuno-phenotype throughout, and these cases most probably represent morphologic mimicry and variation within tumors of a single histotype. Synthesis of molecular data further reduces the incidence of mixed carcinomas. On the basis of these results, true mixed carcinomas with both morphologic and molecular support for the presence of >1 histotype within a given tumor represent <1% of EOCs.

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma, Mucinous / chemistry
  • Adenocarcinoma, Mucinous / diagnosis*
  • Adenocarcinoma, Mucinous / genetics
  • Adenocarcinoma, Mucinous / pathology
  • Alberta
  • Biomarkers, Tumor* / analysis
  • Biomarkers, Tumor* / genetics
  • Biopsy
  • British Columbia
  • Carcinoma, Endometrioid / chemistry
  • Carcinoma, Endometrioid / diagnosis*
  • Carcinoma, Endometrioid / genetics
  • Carcinoma, Endometrioid / pathology
  • Carcinoma, Ovarian Epithelial
  • DNA Mutational Analysis
  • Europe
  • Female
  • Gene Expression Profiling
  • Genetic Predisposition to Disease
  • Humans
  • Immunohistochemistry
  • Neoplasms, Complex and Mixed / chemistry
  • Neoplasms, Complex and Mixed / diagnosis*
  • Neoplasms, Complex and Mixed / genetics
  • Neoplasms, Complex and Mixed / pathology
  • Neoplasms, Glandular and Epithelial / chemistry
  • Neoplasms, Glandular and Epithelial / diagnosis*
  • Neoplasms, Glandular and Epithelial / genetics
  • Neoplasms, Glandular and Epithelial / pathology
  • Ovarian Neoplasms / chemistry
  • Ovarian Neoplasms / diagnosis*
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / pathology
  • Phenotype
  • Predictive Value of Tests

Substances

  • Biomarkers, Tumor